Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells
In this study, we investigated the synergistic effect of co-administration of osimertinib and HAD-B1 using gefitinib-resistant non-small cell lung cancer cells, HCC827-GR. HAD-B1 is composed of 4 natural drugs, Panax Notoginseng Radix, Panax ginseng C. A. Meyer, Cordyceps militaris, and Boswellia ca...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Integrative Cancer Therapies |
| Online Access: | https://doi.org/10.1177/15347354241307006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525446237224960 |
|---|---|
| author | Eun-Ju Ko KMD, PhD Eun-Bin Kwag PhD Ji-Hye Park KMD, PhD Sung-Hyuk Cho MS So-Jung Park KMD, PhD Mi-Kyung Jung KMD, PhD In-Cheol Kang PhD Hwa-Seung Yoo KMD, PhD |
| author_facet | Eun-Ju Ko KMD, PhD Eun-Bin Kwag PhD Ji-Hye Park KMD, PhD Sung-Hyuk Cho MS So-Jung Park KMD, PhD Mi-Kyung Jung KMD, PhD In-Cheol Kang PhD Hwa-Seung Yoo KMD, PhD |
| author_sort | Eun-Ju Ko KMD, PhD |
| collection | DOAJ |
| description | In this study, we investigated the synergistic effect of co-administration of osimertinib and HAD-B1 using gefitinib-resistant non-small cell lung cancer cells, HCC827-GR. HAD-B1 is composed of 4 natural drugs, Panax Notoginseng Radix, Panax ginseng C. A. Meyer, Cordyceps militaris, and Boswellia carterii Birdwood, and has been reported to have therapeutic effects on patients with advanced non-small cell lung cancer in several studies. Resistance to gefitinib in HCC827 cells was acquired through MET activity. Co-treatment with osimertinib and HAD-B1 reduced the cell viability of HCC827-GR cells. In addition, phosphorylation of MET and ERK were effectively suppressed for HCC827-GR cells. And, compared to when osimertinib and HAD-B1 were administered alone, cell proliferation was significantly inhibited and apoptosis was effectively induced when osimertinib and HAD-B1 were co-administered to HCC827-GR cells. We found that the synergistic effect of osimertinib and HAD-B1 combination therapy resulted in cancer cell death and cell cycle arrest by targeting the ERK and mTOR signaling pathways. In conclusion, this study confirmed that the combination of osimertinib, a third-generation anticancer drug, and HAD-B1, a natural anticancer drug, had a potentially synergistic effect on non-small cell lung cancer resistant to EGFR-targeted anticancer drugs. |
| format | Article |
| id | doaj-art-44cc8d37190145ecaeea61988076d257 |
| institution | Kabale University |
| issn | 1552-695X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Integrative Cancer Therapies |
| spelling | doaj-art-44cc8d37190145ecaeea61988076d2572025-01-17T11:03:43ZengSAGE PublishingIntegrative Cancer Therapies1552-695X2025-01-012410.1177/15347354241307006Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer CellsEun-Ju Ko KMD, PhD0Eun-Bin Kwag PhD1Ji-Hye Park KMD, PhD2Sung-Hyuk Cho MS3So-Jung Park KMD, PhD4Mi-Kyung Jung KMD, PhD5In-Cheol Kang PhD6Hwa-Seung Yoo KMD, PhD7Cha Ilsan Medical Center of Cha University, Ilsan, Republic of KoreaIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USASeoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of KoreaInnopharmascreen, Inc., Incheon, Republic of KoreaPusan National University of Korean Medicine Hospital, Busan, Republic of KoreaKorean Institute of Oriental Medicine, Daejeon, Republic of KoreaHoseo University, Asan, Republic of KoreaSeoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of KoreaIn this study, we investigated the synergistic effect of co-administration of osimertinib and HAD-B1 using gefitinib-resistant non-small cell lung cancer cells, HCC827-GR. HAD-B1 is composed of 4 natural drugs, Panax Notoginseng Radix, Panax ginseng C. A. Meyer, Cordyceps militaris, and Boswellia carterii Birdwood, and has been reported to have therapeutic effects on patients with advanced non-small cell lung cancer in several studies. Resistance to gefitinib in HCC827 cells was acquired through MET activity. Co-treatment with osimertinib and HAD-B1 reduced the cell viability of HCC827-GR cells. In addition, phosphorylation of MET and ERK were effectively suppressed for HCC827-GR cells. And, compared to when osimertinib and HAD-B1 were administered alone, cell proliferation was significantly inhibited and apoptosis was effectively induced when osimertinib and HAD-B1 were co-administered to HCC827-GR cells. We found that the synergistic effect of osimertinib and HAD-B1 combination therapy resulted in cancer cell death and cell cycle arrest by targeting the ERK and mTOR signaling pathways. In conclusion, this study confirmed that the combination of osimertinib, a third-generation anticancer drug, and HAD-B1, a natural anticancer drug, had a potentially synergistic effect on non-small cell lung cancer resistant to EGFR-targeted anticancer drugs.https://doi.org/10.1177/15347354241307006 |
| spellingShingle | Eun-Ju Ko KMD, PhD Eun-Bin Kwag PhD Ji-Hye Park KMD, PhD Sung-Hyuk Cho MS So-Jung Park KMD, PhD Mi-Kyung Jung KMD, PhD In-Cheol Kang PhD Hwa-Seung Yoo KMD, PhD Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells Integrative Cancer Therapies |
| title | Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells |
| title_full | Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells |
| title_fullStr | Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells |
| title_full_unstemmed | Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells |
| title_short | Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells |
| title_sort | synergistic effect of had b1 and osimertinib against gefitinib resistant hcc827 non small cell lung cancer cells |
| url | https://doi.org/10.1177/15347354241307006 |
| work_keys_str_mv | AT eunjukokmdphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT eunbinkwagphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT jihyeparkkmdphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT sunghyukchoms synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT sojungparkkmdphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT mikyungjungkmdphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT incheolkangphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells AT hwaseungyookmdphd synergisticeffectofhadb1andosimertinibagainstgefitinibresistanthcc827nonsmallcelllungcancercells |